查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108232

2035年前蛋白質折疊人工智慧市場分析和預測：按類型、產品、服務、技術、組件、應用、部署、最終用戶和功能分類。

AI for Protein Folding Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Deployment, End User, Functionality
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球蛋白質折疊人工智慧市場預計將從2025年的28億美元成長到2035年的166億美元，複合年成長率（CAGR）為19.2%。該市場成長的主要驅動力是生物資料集的快速擴張和全球計算資源投資的不斷增加。預計到2025年，蛋白質資料庫（PDB）中實驗確定的生物分子結構將超過25萬個，為人工智慧模型開發奠定堅實的基礎。目前，公開可用的蛋白質結構資源已包含數億個預測結構，顯著擴展了可用的生物資訊。北美、歐洲和亞太地區的各國政府持續增加對基因組學、生物技術和人工智慧研發的投入。產業分析師普遍預測，在研發、數位化、精準醫療計畫以及製藥領域生技藥品加速發展的推動下，人工智慧驅動的蛋白質建模解決方案將在整個預測期內實現兩位數的年成長率。

該市場涵蓋多種技術，例如監督學習、無監督學習、強化學習、遷移學習和深度學習，每種技術都致力於解決蛋白質結構預測中獨特的運算挑戰。監督學習利用實驗檢驗的蛋白質資料集來提高預測精度，而無監督學習則從未標記的生物資料中識別隱藏的結構關係。強化學習透過迭代回饋機制最佳化分子構象，而遷移學習則透過將預先訓練的生物模型應用於特定的蛋白質家族來提升表現。深度學習憑藉其變壓器架構、圖神經網路和注意力機制等優勢，能夠模擬複雜的分子間相互作用，因此佔主導地位。運算能力的提升和結構資料庫的不斷擴展持續推動著深度學習在藥物研發和結構生物學領域的應用。

市場區隔
類型 監督學習、無監督學習、強化學習、遷移學習、深度學習等等。
產品 軟體工具、平台、人工智慧模型、資料庫等。
服務 諮詢、整合和部署、支援和維護、培訓和教育以及其他服務。
科技 神經網路、自然語言處理、電腦視覺、機器學習等。
成分 硬體、軟體、服務及其他
目的 藥物發現、基因體學、結構生物學、生物技術及其他
發展 雲端、本地部署、混合部署及其他
最終用戶 製藥公司、生技公司、研究機構、學術機構、醫療保健提供者及其他
功能 蛋白質結構預測、蛋白質設計、蛋白質-蛋白質交互作用等等。

該產品系列包括軟體工具、資料庫、平台和專用試劑盒，旨在支援人工智慧驅動的蛋白質折疊工作流程。軟體工具提供預測建模、視覺化、檢驗和結構分析功能，而精心整理的資料庫則記錄了實驗確定的蛋白質結構和生物學註釋，用於演算法訓練。整合的雲端和本地平台支援跨組織的可擴展運算、協作研究和工作流程自動化。實驗檢驗盒透過促進蛋白質結構的實驗室驗證，補充了計算預測結果。與高效能運算、雲端基礎設施和實驗室資訊系統的更深入整合，提高了營運效率，增強了研究生產力，並拓展了其在藥物發現、合成生物學和蛋白質工程等領域的應用範圍。

區域概覽

北美憑藉其先進的生物技術生態系統、強大的藥物研發能力以及人工智慧技術的廣泛應用，保持著主導地位。該地區受益於完善的高效能運算基礎設施、成熟的學術研究機構以及對計算生物學的大量投資。公共資金對基因組學、生物醫學創新和人工智慧研究的支持，促進了技術的持續進步；而科技公司、製藥公司和研究機構之間的合作則加速了商業化進程。主要雲端服務供應商和專業人工智慧開發公司的存在，進一步加劇了區域競爭，並推動了蛋白質折疊解決方案在藥物發現和生物醫學研究應用領域的廣泛應用。

亞太地區正透過增加對生物技術基礎設施、國家人工智慧戰略和醫藥創新項目的投資，進一步提升其影響力。中國、日本、韓國、新加坡和印度等國家正透過研究夥伴關係和政府主導的資助舉措，加強其計算生物學能力。國內生物製藥生產的快速成長、基因組研究的拓展以及雲端運算資源的日益普及，正在推動人工智慧驅動的蛋白質建模平台的應用。大學、實驗室和生物技術新創公司正與國際技術供應商日益密切的合作，這不僅促進了技術進步，也為在醫療保健和生命科學行業的更廣泛商業化應用創造了有利條件。

主要趨勢和促進因素

人工智慧演算法在蛋白質折疊方面的進展

受機器學習演算法（尤其是深度學習和神經網路）進步的推動，用於蛋白質折疊的人工智慧市場正經歷快速成長。這些技術顯著提高了蛋白質結構預測的準確性和速度，這對藥物發現和開發至關重要。由於人工智慧現在能夠更有效率地預測蛋白質結構，從而加速研究並降低成本，它已成為生物技術和製藥行業的重要工具。

利用人工智慧技術，透過蛋白質結構預測和設計的創新，加速藥物發現。

對更快、更經濟高效的藥物研發日益成長的需求，正推動人工智慧在蛋白質折疊技術領域的應用。製藥和生物技術公司擴大利用人工智慧模型來縮短蛋白質結構解析時間、減少實驗工作量、提高靶點識別的準確性並最佳化候選化合物的選擇。在不斷擴展的計算基礎設施和不斷發展的合作研究生態系統的支持下，對生物製藥、精準醫療、罕見疾病研究和計算生物學的投資不斷增加，進一步推動了全球市場的成長。

目錄

第1章：摘要整理

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 監督式學習
    • 無監督學習
    • 強化學習
    • 遷移學習
    • 深度學習
    • 其他
  • 市場規模及預測：依產品分類
    • 軟體工具
    • 平台
    • 人工智慧模型
    • 資料庫
    • 其他
  • 市場規模及預測：依服務分類
    • 諮詢
    • 整合與部署
    • 支援和維護
    • 培訓和教育
    • 其他
  • 市場規模及預測：依技術分類
    • 神經網路
    • 自然語言處理
    • 電腦視覺
    • 機器學習
    • 其他
  • 市場規模及預測：依組件分類
    • 硬體
    • 軟體
    • 服務
    • 其他
  • 市場規模及預測：依應用領域分類
    • 藥物發現
    • 基因組學
    • 結構生物學
    • 生物技術
    • 其他
  • 市場規模及預測：依市場細分
    • 雲
    • 現場
    • 混合
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 製藥公司
    • 生技公司
    • 研究機構
    • 學術機構
    • 醫療服務提供方
    • 其他
  • 市場規模及預測：依功能分類
    • 蛋白質結構預測
    • 蛋白質設計
    • 蛋白質-蛋白質相互作用
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 定價和成本利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 大公司的策略

第8章：公司簡介

  • DeepMind
  • Insilico Medicine
  • Atomwise
  • Schrodinger
  • Relay Therapeutics
  • XtalPi
  • BenevolentAI
  • Cyclica
  • BioSymetrics
  • Arzeda
  • ProteinQure
  • Exscientia
  • Cloud Pharmaceuticals
  • Peptone
  • Molecular AI
  • ReviveMed
  • Valence Discovery
  • AstraZeneca
  • Bristol Myers Squibb
  • Pfizer

第9章 關於我們

簡介目錄
Product Code: GIS10834

The global AI for Protein Folding Market is projected to grow from $2.8 billion in 2025 to $16.6 billion by 2035, at a compound annual growth rate (CAGR) of 19.2%. The market is supported by rapidly expanding biological datasets and increasing computational investments worldwide. The Protein Data Bank surpassed 250,000 experimentally determined biomolecular structures in 2025, providing a robust foundation for AI model development. Publicly available protein structure resources now contain hundreds of millions of predicted structures, substantially expanding accessible biological information. Governments across North America, Europe, and Asia-Pacific continue increasing funding for genomics, biotechnology, and artificial intelligence research. Industry analysts broadly project double-digit annual growth for AI-enabled protein modeling solutions through the forecast period, driven by pharmaceutical R&D digitalization, precision medicine initiatives, and accelerated biologics development.

The market encompasses supervised learning, unsupervised learning, reinforcement learning, transfer learning, and deep learning techniques, each addressing distinct computational challenges in protein structure prediction. Supervised learning leverages experimentally validated protein datasets to improve predictive accuracy, while unsupervised learning identifies hidden structural relationships from unlabeled biological data. Reinforcement learning optimizes molecular conformations through iterative feedback mechanisms, and transfer learning enhances performance by adapting pretrained biological models to specialized protein families. Deep learning dominates due to transformer architectures, graph neural networks, and attention mechanisms capable of modeling complex molecular interactions. Growing computational capabilities and expanding structural databases continue supporting adoption across pharmaceutical research and structural biology.

Market Segmentation
TypeSupervised Learning, Unsupervised Learning, Reinforcement Learning, Transfer Learning, Deep Learning, Others
ProductSoftware Tools, Platforms, AI Models, Databases, Others
ServicesConsulting, Integration and Deployment, Support and Maintenance, Training and Education, Others
TechnologyNeural Networks, Natural Language Processing, Computer Vision, Machine Learning, Others
ComponentHardware, Software, Services, Others
ApplicationDrug Discovery, Genomics, Structural Biology, Biotechnology, Others
DeploymentCloud, On-Premises, Hybrid, Others
End UserPharmaceutical Companies, Biotechnology Firms, Research Institutes, Academic Institutions, Healthcare Providers, Others
FunctionalityProtein Structure Prediction, Protein Design, Protein-Protein Interaction, Others

The product landscape includes software tools, databases, platforms, and specialized kits supporting AI-driven protein folding workflows. Software tools provide predictive modeling, visualization, validation, and structural analysis capabilities, while curated databases supply experimentally determined protein structures and biological annotations for algorithm training. Integrated cloud and on-premises platforms enable scalable computing, collaborative research, and workflow automation across organizations. Experimental validation kits complement computational predictions by facilitating laboratory confirmation of protein structures. Increasing integration with high-performance computing, cloud infrastructure, and laboratory information systems strengthens operational efficiency, improves research productivity, and supports expanding applications in drug development, synthetic biology, and protein engineering.

Geographical Overview

North America maintains a leading position due to its advanced biotechnology ecosystem, strong pharmaceutical research capabilities, and widespread adoption of artificial intelligence technologies. The region benefits from extensive high-performance computing infrastructure, established academic research institutions, and significant investments in computational biology. Public funding for genomics, biomedical innovation, and AI research supports continuous technological advancement, while collaboration among technology companies, pharmaceutical manufacturers, and research organizations accelerates commercialization. The presence of leading cloud service providers and specialized AI developers further strengthens regional competitiveness, enabling broad deployment of protein folding solutions across drug discovery and biomedical research applications.

Asia-Pacific continues expanding its presence through increasing investments in biotechnology infrastructure, national artificial intelligence strategies, and pharmaceutical innovation programs. Countries including China, Japan, South Korea, Singapore, and India are strengthening computational biology capabilities through research partnerships and government-backed funding initiatives. Rapid growth in domestic biopharmaceutical manufacturing, expanding genomic research, and greater availability of cloud computing resources encourage adoption of AI-driven protein modeling platforms. Universities, research laboratories, and biotechnology startups increasingly collaborate with international technology providers, supporting technological advancement and creating favorable conditions for broader commercial deployment across healthcare and life sciences industries.

Key Trends and Drivers

Advancements in AI Algorithms for Protein Folding:

The AI for protein folding market is experiencing rapid growth due to advancements in machine learning algorithms, particularly deep learning and neural networks. These technologies have significantly improved the accuracy and speed of protein structure predictions, which are crucial for drug discovery and development. The ability to predict protein structures more efficiently accelerates research timelines and reduces costs, making AI a valuable tool in biotechnology and pharmaceutical industries.

Accelerating Drug Discovery with AI-Driven Protein Structure Prediction and Design Innovation:

Growing demand for faster and more cost-effective drug discovery is driving adoption of AI for protein folding technologies. Pharmaceutical and biotechnology companies increasingly utilize AI models to shorten protein structure determination timelines, reduce laboratory experimentation, improve target identification, and optimize candidate selection. Rising investments in biologics, precision medicine, rare disease research, and computational biology, supported by expanding computing infrastructure and collaborative research ecosystems, continue strengthening market growth worldwide.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by Deployment
  • 2.8 Key Market Highlights by End User
  • 2.9 Key Market Highlights by Functionality

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Supervised Learning
    • 4.1.2 Unsupervised Learning
    • 4.1.3 Reinforcement Learning
    • 4.1.4 Transfer Learning
    • 4.1.5 Deep Learning
    • 4.1.6 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Software Tools
    • 4.2.2 Platforms
    • 4.2.3 AI Models
    • 4.2.4 Databases
    • 4.2.5 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consulting
    • 4.3.2 Integration and Deployment
    • 4.3.3 Support and Maintenance
    • 4.3.4 Training and Education
    • 4.3.5 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Neural Networks
    • 4.4.2 Natural Language Processing
    • 4.4.3 Computer Vision
    • 4.4.4 Machine Learning
    • 4.4.5 Others
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Hardware
    • 4.5.2 Software
    • 4.5.3 Services
    • 4.5.4 Others
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Drug Discovery
    • 4.6.2 Genomics
    • 4.6.3 Structural Biology
    • 4.6.4 Biotechnology
    • 4.6.5 Others
  • 4.7 Market Size & Forecast by Deployment (2020-2035)
    • 4.7.1 Cloud
    • 4.7.2 On-Premises
    • 4.7.3 Hybrid
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by End User (2020-2035)
    • 4.8.1 Pharmaceutical Companies
    • 4.8.2 Biotechnology Firms
    • 4.8.3 Research Institutes
    • 4.8.4 Academic Institutions
    • 4.8.5 Healthcare Providers
    • 4.8.6 Others
  • 4.9 Market Size & Forecast by Functionality (2020-2035)
    • 4.9.1 Protein Structure Prediction
    • 4.9.2 Protein Design
    • 4.9.3 Protein-Protein Interaction
    • 4.9.4 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 Deployment
      • 5.2.1.8 End User
      • 5.2.1.9 Functionality
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 Deployment
      • 5.2.2.8 End User
      • 5.2.2.9 Functionality
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 Deployment
      • 5.2.3.8 End User
      • 5.2.3.9 Functionality
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 Deployment
      • 5.3.1.8 End User
      • 5.3.1.9 Functionality
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 Deployment
      • 5.3.2.8 End User
      • 5.3.2.9 Functionality
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 Deployment
      • 5.3.3.8 End User
      • 5.3.3.9 Functionality
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 Deployment
      • 5.4.1.8 End User
      • 5.4.1.9 Functionality
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 Deployment
      • 5.4.2.8 End User
      • 5.4.2.9 Functionality
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 Deployment
      • 5.4.3.8 End User
      • 5.4.3.9 Functionality
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 Deployment
      • 5.4.4.8 End User
      • 5.4.4.9 Functionality
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 Deployment
      • 5.4.5.8 End User
      • 5.4.5.9 Functionality
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 Deployment
      • 5.4.6.8 End User
      • 5.4.6.9 Functionality
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 Deployment
      • 5.4.7.8 End User
      • 5.4.7.9 Functionality
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 Deployment
      • 5.5.1.8 End User
      • 5.5.1.9 Functionality
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 Deployment
      • 5.5.2.8 End User
      • 5.5.2.9 Functionality
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 Deployment
      • 5.5.3.8 End User
      • 5.5.3.9 Functionality
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 Deployment
      • 5.5.4.8 End User
      • 5.5.4.9 Functionality
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 Deployment
      • 5.5.5.8 End User
      • 5.5.5.9 Functionality
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 Deployment
      • 5.5.6.8 End User
      • 5.5.6.9 Functionality
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 Deployment
      • 5.6.1.8 End User
      • 5.6.1.9 Functionality
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 Deployment
      • 5.6.2.8 End User
      • 5.6.2.9 Functionality
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 Deployment
      • 5.6.3.8 End User
      • 5.6.3.9 Functionality
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 Deployment
      • 5.6.4.8 End User
      • 5.6.4.9 Functionality
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 Deployment
      • 5.6.5.8 End User
      • 5.6.5.9 Functionality

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 DeepMind
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Insilico Medicine
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Atomwise
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Schrodinger
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Relay Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 XtalPi
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 BenevolentAI
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Cyclica
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 BioSymetrics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Arzeda
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 ProteinQure
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Exscientia
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Cloud Pharmaceuticals
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Peptone
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Molecular AI
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 ReviveMed
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Valence Discovery
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 AstraZeneca
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Bristol Myers Squibb
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Pfizer
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us